BridgeMD
New treatment option for Ovarian Cancer
Official title Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
ClinicalTrials.gov ID: NCT04997096
What this study is testing
- What it's testing
- The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
- Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
- ≥18 years, children under the age of 18 will be excluded due to rarity of disease
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Able to read, write, and understand English
You likely can't join if
- Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
- Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
- Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
- Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
See the full eligibility criteria
- Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
- Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
- ≥18 years, children under the age of 18 will be excluded due to rarity of disease
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Able to read, write, and understand English
- Ability to understand and the willingness to sign an informed consent document
- Willing to undergo two venous blood draws for the study
- Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
- Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
- Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
- Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.